Patents by Inventor Olov Sterner

Olov Sterner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200087274
    Abstract: Disclosed are sulfonamide analogues of galiellactone of formula (I) as STAT3-inhibitors for use in the treatment of a STAT3 signaling related disorder, e.g. solid cancers, hematological cancers, benign tumors, hyperproliferative diseases, inflammations, autoimmune diseases, graft or transplant rejections, delayed physiological function of grafts or transplants, neurodegenerative diseases and viral infections. The sulfonamide comprises a cyclic substituent.
    Type: Application
    Filed: December 5, 2017
    Publication date: March 19, 2020
    Inventors: Martin JOHANSSON, Olov STERNER
  • Patent number: 10538500
    Abstract: Prodrugs of galiellactone, and derivatives thereof, are provided by reacting the parent compound, e.g. galiellactone, with a thiol. Such drugs may be administered orally to treat cancer and other proliferative diseases.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: January 21, 2020
    Assignee: Glactone Pharma Development AB
    Inventors: Martin Johansson, Olov Sterner
  • Patent number: 10383841
    Abstract: The invention relates to the use of at least davanone and 1,8-cineol for the manufacture of an antimicrobial and/or antiinflammatory composition as well as a method of producing said composition.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: August 20, 2019
    Assignee: DeNovaStella AB
    Inventors: Jan Faergemann, Thomas Hedner, Olov Sterner, Lars Bjork
  • Patent number: 10351577
    Abstract: Ether analogues of galiellalactone, methods of preparing the analogues, and use of the analogues in the treatment of cancer are disclosed.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: July 16, 2019
    Assignee: Glactone Pharma Development AB
    Inventors: Johansson Martin, Olov Sterner, Anders Bjartell, Rebecka Hellsten, Zilma Escobar
  • Publication number: 20190110983
    Abstract: The present invention relates to a pharmaceutical formulation for vaginal administration, wherein the formulation comprises a pharmaceutical acceptable excipient and glucono ?-lactone, wherein the glucono ?-lactone is present in an amount of 5 to 99 wt % of the formulation. The invention also relates to a pharmaceutical formulation according to the invention for use in the prevention or treatment of a urogenital fungal infection. Furthermore, the invention relates to glucono ?-lactone (formula (III)), for use in the in the prevention or treatment of a fungal infection.
    Type: Application
    Filed: April 6, 2017
    Publication date: April 18, 2019
    Inventors: Ulf Ellervik, Olov Sterner, Helena Strevens, Sophie Manner
  • Publication number: 20180346435
    Abstract: Prodrugs of galiellactone, and derivatives thereof, are provided by reacting the parent compound, e.g. galiellactone, with a thiol. Such drugs may be administered orally to treat cancer and other proliferative diseases.
    Type: Application
    Filed: August 9, 2018
    Publication date: December 6, 2018
    Applicant: Glactone Pharma Development AB
    Inventors: Martin Johansson, Olov Sterner
  • Patent number: 10077246
    Abstract: Prodrugs (I) and (Ia) of galiellactone, and derivatives thereof, are provided by reacting the parent compound, e.g. galiellactone, with a thiol. Such drugs may be administered orally to treat cancer and other proliferative diseases.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: September 18, 2018
    Assignee: Glactone Pharma Development AB
    Inventors: Martin Johansson, Olov Sterner
  • Publication number: 20180155360
    Abstract: Ether analogues of galiellalactone, methods of preparing the analogues, and use of the analogues in the treatment of cancer are disclosed.
    Type: Application
    Filed: June 2, 2016
    Publication date: June 7, 2018
    Applicant: Glactone Pharma Development AB
    Inventors: Johansson Martin, Olov Sterner, Anders Bjartell, Rebecka Hellsten, Zilma Escobar
  • Publication number: 20170015644
    Abstract: Prodrugs (I) and (Ia) of galiellactone, and derivatives thereof, are provided by reacting the parent compound, e.g. galiellactone, with a thiol. Such drugs may be administered orally to treat cancer and other proliferative diseases.
    Type: Application
    Filed: March 6, 2015
    Publication date: January 19, 2017
    Applicant: Glactone Pharma Development AB
    Inventors: Martin JOHANSSON, Olov STERNER
  • Patent number: 9370502
    Abstract: A composition comprising i) oligomeric lactic acid with the following formula (I) wherein n is an integer from 2 to 20, from 2 to 19, or from 2 to 18, and wherein from about 10 to about 20% w/w of the total weight of the oligomeric lactic acid is a trimer, HL3, having n equal to 2, wherein the number average molecular weight Mn of the oligomeric lactic acid is from about 200 to about 500, and ii) a mucoadhesive agent.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: June 21, 2016
    Assignee: LACCURE AB
    Inventors: Olov Sterner, Sören Kulstad, Jeanette Robertsson, Malgorzata Sznitowska, Werner Schubert
  • Patent number: 9315444
    Abstract: The invention relates to the use of one or more oligomers of lactic acid or a lactic acid oligomeric product for the prophylaxis and/or treatment of a disease or condition that benefits from an acidic environment, especially a gynaecological infection including a bacterial infection such as bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethritis, a fungal infection, such as candidosis (Candida albicans), cryptococcosis, actinomycosis, or a viral infection, such as Human Immunodefiency Virus (HIV), Herpes Simplex Virus (HSV), Human Papilloma Virus (HPV).
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: April 19, 2016
    Assignee: Laccure AB
    Inventors: Greg Batcheller, Thomas Hedner, Joergen Johnsson, Werner Schubert, Christer Sjoegren, Olov Sterner, Malgorzat Sznitowska
  • Patent number: 9150531
    Abstract: The present invention discloses novel compounds useful for the inhibition of IL-6/STAT signaling and/or PI3K/NF-?B signaling in the treatment of associated diseases or conditions, e.g. cancer. A pharmaceutical composition comprising such novel compounds, its use and a method thereof, is also disclosed.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: October 6, 2015
    Assignee: Glactone Pharma Development AB
    Inventors: Ritha Gidlöf, Martin Johansson, Olov Sterner, Eduardo Muñoz
  • Patent number: 9066947
    Abstract: The disclosure describes compounds of formula I, wherein the wedged bonds, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, X and Y have meanings given in the description, and pharmaceutically-acceptable salts thereof; and methods of using such compounds useful in the treatment of cancer and conditions affected by inhibition of angiogenesis. Also provided, are processes for the preparation of formula I, by reacting formula I with other compounds; and processes for the preparation of a pharmaceutical formulation by bringing into association, a compound of formula I, with therapeutic agents and/or a pharmaceutically-acceptable adjuvant, diluent, or carrier.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: June 30, 2015
    Assignee: EVEREST BIOSCIENCES, INC.
    Inventors: Jenny Persson, Rikard Larsson, Olov Sterner, Martin Johansson
  • Publication number: 20150164848
    Abstract: A composition comprising i) oligomeric lactic acid with the following formula (I) wherein n is an integer from 2 to 20, from 2 to 19, or from 2 to 18, and wherein from about 10 to about 20% w/w of the total weight of the oligomeric lactic acid is a trimer, HL3, having n equal to 2, wherein the number average molecular weight Mn of the oligomeric lactic acid is from about 200 to about 500, and ii) a mucoadhesive agent.
    Type: Application
    Filed: July 5, 2013
    Publication date: June 18, 2015
    Applicant: LACCURE AB
    Inventors: Olov Sterner, Sören Kulstad, Jeanette Robertsson, Malgorzata Sznitowska, Werner Schubert
  • Publication number: 20150025142
    Abstract: The invention relates to the use of one or more oligomers of lactic acid or a lactic acid oligomeric product for the prophylaxis and/or treatment of a disease or condition that benefits from an acidic environment, especially a gynaecological infection including a bacterial infection such as bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethritis, a fungal infection, such as candidosis (Candida albicans), cryptococcosis, actinomycosis, or a viral infection, such as Human Immunodefiency Virus (HIV), Herpes Simplex Virus (HSV), Human Papilloma Virus (HPV).
    Type: Application
    Filed: June 20, 2014
    Publication date: January 22, 2015
    Inventors: Greg Batcheller, Thomas Hedner, Joergen Johnsson, Werner Schubert, Christer Sjoegren, Olov Sterner, Malgorzat Sznitowska
  • Patent number: 8912232
    Abstract: The invention relates to an oligomeric lactic acid composition comprising one or more oligomers of lactic acid or a pharmaceutical composition comprising an oligomeric lactic acid composition for the prophylaxis and/or treatment of a disease or condition that benefits from an acidic environment.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: December 16, 2014
    Assignee: Laccure AB
    Inventors: Greg Batcheller, Thomas Hedner, Joergen Johnsson, Werner Schubert, Christer Sjoegren, Olov Sterner, Malgorzat Sznitowska
  • Publication number: 20140235644
    Abstract: The disclosure describes compounds of formula I, wherein the wedged bonds, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, X and Y have meanings given in the description, and pharmaceutically-acceptable salts thereof; and methods of using such compounds useful in the treatment of cancer and conditions affected by inhibition of angiogenesis. Also provided, are processes for the preparation of formula I, by reacting formula I with other compounds; and processes for the preparation of a pharmaceutical formulation by bringing into association, a compound of formula I, with therapeutic agents and/or a pharmaceutically-acceptable adjuvant, diluent, or carrier.
    Type: Application
    Filed: April 28, 2014
    Publication date: August 21, 2014
    Applicant: Everest Biosciences, Inc.
    Inventors: Jenny Persson, Rikard Larsson, Olov Sterner, Martin Johansson
  • Patent number: 8809355
    Abstract: The present invention relates to novel compounds of the general formula (I) having anxiolytic, anticonvulsant, sedative-hypnotic and myorelaxant conditions as well as anxiogenic, somnolytic and convulsant conditions in mammals, including humans, as GABAA receptor modulator.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: August 19, 2014
    Assignee: Innovationspatent Sverige AB
    Inventors: Mogens Peter Cherly Nielsen, Tommy Liljefors, Jakob Alexander Nilsson, Olov A Sterner
  • Patent number: 8802654
    Abstract: Herein are disclosed novel compounds according to Formula (I) and aggregates comprising such compounds. These aggregates are useful to treat and prevent ocular infections caused by a vims, which virus binds to terminal sialic residues present on the cell surface of the cell to be infected by the virus.
    Type: Grant
    Filed: July 5, 2010
    Date of Patent: August 12, 2014
    Assignee: Adenovir Pharma AB
    Inventors: Olov Sterner, Ulf Ellervik, Karolina Aplander, Anders Carlsson
  • Patent number: 8754086
    Abstract: The disclosure describes compounds of formula I, wherein the wedged bonds, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, X and Y have meanings given in the description, and pharmaceutically-acceptable salts thereof; and methods of using such compounds useful in the treatment of cancer and conditions affected by inhibition of angiogenesis. Also provided, are processes for the preparation of formula I, by reacting formula I with other compounds; and processes for the preparation of a pharmaceutical formulation by bringing into association, a compound of formula I, with therapeutic agents and/or a pharmaceutically-acceptable adjuvant, diluent, or carrier.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: June 17, 2014
    Assignee: Everest Biosciences, Inc.
    Inventors: Jenny Persson, Rikard Larsson, Olov Sterner, Martin Johansson